Kite Pharma, Inc. Insider Trading for September 2017
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Kite Pharma, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Kite Pharma, Inc. for September 2017.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Sep 27 2017 | KITE | Kite Pharma, Inc. | Tomasello Shawn | Chief Commercial Of ... | Sell | S | 179.66 | 4,203 | 755,127 | 61,068 | 65.3 K to 61.1 K (-6.44 %) |
Sep 27 2017 | KITE | Kite Pharma, Inc. | Tomasello Shawn | Chief Commercial Of ... | Grant | A | 0.00 | 4,500 | 0 | 65,271 | 60.8 K to 65.3 K (+7.40 %) |
Sep 27 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 179.66 | 3,171 | 569,714 | 21,693 | 24.9 K to 21.7 K (-12.75 %) |
Sep 27 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Grant | A | 0.00 | 6,000 | 0 | 24,864 | 18.9 K to 24.9 K (+31.81 %) |
Sep 27 2017 | KITE | Kite Pharma, Inc. | MOORE TIMOTHY L. | EVP, Technical Oper ... | Sell | S | 179.66 | 4,228 | 759,619 | 45,661 | 49.9 K to 45.7 K (-8.47 %) |
Sep 27 2017 | KITE | Kite Pharma, Inc. | MOORE TIMOTHY L. | EVP, Technical Oper ... | Grant | A | 0.00 | 8,000 | 0 | 49,889 | 41.9 K to 49.9 K (+19.10 %) |
Sep 27 2017 | KITE | Kite Pharma, Inc. | MOORE TIMOTHY L. | EVP, Technical Oper ... | Sell | S | 83.31 | 7,511 | 625,741 | 41,889 | 49.4 K to 41.9 K (-15.20 %) |
Sep 27 2017 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 179.66 | 5,283 | 949,164 | 25,824 | 31.1 K to 25.8 K (-16.98 %) |
Sep 27 2017 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Grant | A | 0.00 | 10,000 | 0 | 31,107 | 21.1 K to 31.1 K (+47.38 %) |
Sep 27 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 179.66 | 7,927 | 1,424,196 | 57,423 | 65.4 K to 57.4 K (-12.13 %) |
Sep 27 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Grant | A | 0.00 | 15,000 | 0 | 65,350 | 50.4 K to 65.4 K (+29.79 %) |
Sep 27 2017 | KITE | Kite Pharma, Inc. | JENKINSON PAUL L | Chief Financial Off ... | Sell | S | 179.66 | 948 | 170,321 | 9,462 | 10.4 K to 9.5 K (-9.11 %) |
Sep 27 2017 | KITE | Kite Pharma, Inc. | JENKINSON PAUL L | Chief Financial Off ... | Grant | A | 0.00 | 2,500 | 0 | 10,410 | 7.9 K to 10.4 K (+31.61 %) |
Sep 27 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Sell | S | 179.66 | 4,228 | 759,619 | 121,567 | 125.8 K to 121.6 K (-3.36 %) |
Sep 27 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Grant | A | 0.00 | 8,000 | 0 | 125,795 | 117.8 K to 125.8 K (+6.79 %) |
Sep 27 2017 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Sell | S | 179.66 | 26,347 | 4,733,605 | 109,160 | 135.5 K to 109.2 K (-19.44 %) |
Sep 27 2017 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Grant | A | 0.00 | 50,000 | 0 | 135,507 | 85.5 K to 135.5 K (+58.47 %) |